bioMérieux stock
Price history
−13.62% over the period1 year: from €105.70 (November 20, 2025) to €91.30 (November 20, 2026), −13.62%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €91.30 |
| October 30, 2026 | €90.50 |
| September 30, 2026 | €77.75 |
| August 31, 2026 | €75.05 |
| July 31, 2026 | €69.10 |
| June 30, 2026 | €68.70 |
| May 29, 2026 | €74.35 |
| April 30, 2026 | €71.70 |
| March 31, 2026 | €91.80 |
| February 27, 2026 | €100.00 |
| January 30, 2026 | €97.80 |
| December 31, 2025 | €110.30 |
| November 28, 2025 | €107.90 |
| November 20, 2025 | €105.70 |
At a glance
The company
Develops and sells in vitro diagnostic solutions for infectious diseases, including microbiology, PCR and mass spectrometry systems
Latest results
Quarter to June 30, 2026 · EPS €1.91
TickerLandia's take on bioMérieux
- Priced as usual relative to earnings: P/E on the latest fiscal year 27 vs a median of 32 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 23 vs 34 (−31%) in a group of 11.
- Strong point: Financial strength (84/100 in its group). Weak point: Growth (49/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−21.36% from the 52-week high
Analysts · 13 analysts
Average target€89.04−2.48% vs. price
Buy 2 · Hold 10 · Sell 1 · Hold
TickerLandia Fingerprint: bioMérieux
Compared with similar companies: very high financial strength.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow25
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 19.5 42 EV/EBITDA 9.94 10 P/E (trailing 12 months) 23.4 19 Price/book 2.50 21 Price/sales 2.69 35 Profitabilityaverage55
How much it earns on revenue and capital.
Metric Value Position in group ROA 7.2% 69 Operating margin 16.0% 50 Net margin 11.6% 57 ROE 11.2% 40 Gross margin 56.1% 61 Earnings stabilityaverage57
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.5% 54 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage49
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +4.28% 65 Earnings growth (year over year) +41.90% 78 Revenue growth (year over year) −3.90% 6 Financial strengthvery high84
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 44.0 90 Debt/equitycounts in reverse: lower means more financial strength 0.10 87 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.11 86 Current ratio 2.30 72 Dividendaverage55
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 22 years 68 Payout ratio 25.1% 41 Dividend yield 1.1% 57 Market momentumstrong74
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +30.50% 98 Relative strength (6 months) +28.68% 92 1-year return −13.62% 17 Distance from 200-day average +13.84% 87 Riskaverage45
How much the price swings.
Metric Value Position in group Volatility (60 days) 24.2% 36 Beta (1 year) 0.26 11 Maximum drawdown (12 months) 42.0% 88
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
bioMérieux is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), bioMérieux's P/E today is 27.3, in line with the median of its last 10 fiscal years (32.1; between 24.7 and 37.2 from 2016 to 2025). bioMérieux's P/E (trailing 12 months): 23.4, −31% against the median of a group of 11 similar companies (33.9).
Compared with 11 similar companies
| Metric | bioMérieux | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 23.4 | Low | |
| Forward P/E | 19.5 | Middle | |
| Operating margin | 16.0% | Middle | |
| ROE | 11.2% | Middle | |
| Debt/equity | 0.10 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: bioMérieux. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€1.96B
Latest quarter · Q2 2026
Net income
€226.1M
Latest quarter · Q2 2026
Quarterly net margin
11.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €10.75B
- P/E
- 23.4
- EPS
- €3.90
- Volume
- 112.79K
- Daily trading
- €13.92M
- Dividend yield
- 1.07%
- Last ex-dividend on June 9, 2026
How bioMérieux is changing
All resultsRevenue grew 5.5% a year on average over the last 5 years
Free cash flow equal to 74% of net income
Revenue has grown for 9 fiscal years in a row
Returns
bioMérieux returns with dividends
€1,000 invested in bioMérieux 5 years ago, on November 22, 2021, would be worth €789 today with dividends reinvested: −21.08% in total, −4.63% per year. On price alone it would be €752 (−24.76%).
| Period | bioMérieux | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | +4.70% | +1.14% | €1,047 |
| 6 months | +25.67% | −2.34% | €1,257 |
| Year to date | −17.23% | −2.72% | €828 |
| 1 year | −12.44% | −0.67% | €876 |
| 3 years | −1.85% | +9.39% | €982 |
| 5 years | −21.08% | +11.58% | €789 |
| 10 years | +122.66% | +75.02% | €2,227 |
Over the last 6 months it has done better than 65% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment
The chart in detail
bioMérieux: technical analysis
bioMérieux shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 36.3% below its all-time closing high (€143.40, October 12, 2020).
- Trend
- No clear trend
- RSI (14 sessions)
- 57
- Between 30 and 70
- vs 200-session average
- +13.84%
Support and resistance
Price areas where bioMérieux has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€102.20+11.94%2 touches, last on February 27, 2026
- Last price€91.30
- Support€87.80−3.83%2 touches, last on April 13, 2026
- Support€74.60−18.29%5 touches, last on October 2, 2026
- Support€71.63−21.55%2 touches, last on August 19, 2026
Volatility and risk
Over the last year it has moved little with the CAC 40.
- Beta (1 year) vs CAC 40
- 0.26
- Volatility (60 sessions, annualised)
- 24.2%
- Largest fall in the last year
- −41.99%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
bioMérieux: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for bioMérieux has been May: +3.72% on average, positive in 15 years out of 22. The weakest has been September: −1.01% on average, positive in 12 years out of 23. November, the current month, has been positive in 11 years out of 22 (+0.70% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.63% | +2.67% | 14 of 22 |
| February | −0.31% | −0.74% | 10 of 22 |
| March | +0.87% | +0.01% | 11 of 22 |
| April | −0.53% | −1.98% | 7 of 22 |
| May | +3.72% | +3.14% | 15 of 22 |
| June | −0.53% | +0.33% | 11 of 22 |
| July | +3.42% | +3.59% | 16 of 22 |
| August | +0.28% | −0.15% | 11 of 23 |
| September | −1.01% | +0.47% | 12 of 23 |
| October | +0.86% | −1.44% | 11 of 23 |
| November | +0.70% | −0.06% | 11 of 22 |
| December | +2.79% | +2.20% | 16 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
bioMérieux and its competitors
Many clinicians and laboratories know bioMérieux through VITEK 2, BIOFIRE and VIDAS, the systems used to identify bacteria, test their resistance to antibiotics and detect infections. The range also includes BACT/ALERT blood culture instruments, the VITEK MS mass spectrometry platform and API identification strips. Beyond these instruments, the group supplies culture media, PCR tests for viral respiratory infections and detection kits for the food industry, along with lab consultancy and training. It sells in France, across Europe, Africa, the Middle East, the Americas and Asia Pacific.
- Headquarters
- Marcy-l'Étoile, France
- Employees
- 14,562
- Founded
- 1963
- Chief executive
- Pierre Boulud
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| bioMérieuxBIM | $11.82B | 16.0% | 23.4 | +25.67% |
| QiagenQIA | $10.23B | 26.7% | 28.5 | +50.69% |
| Eurofins ScientificERF | $16.03B | 14.1% | 29.6 | +37.31% |
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| Lonza GroupLONN | $54.2B | 23.5% | 43.2 | +32.22% |
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
Same industry or related industries, similar size. Compare bioMérieux with its competitors · Full profile
